Article ; Online: Neonatal outcomes after neuraminidase inhibitor use during pregnancy: A meta-analysis of cohort studies.
British journal of clinical pharmacology
2021 Volume 88, Issue 3, Page(s) 911–918
Abstract: Aim: Influenza infection poses a severe threat to pregnant mothers, and antiviral treatment is recommended. However, the safety of neuraminidase-inhibitor antiviral medications during pregnancy has not been well described.: Methods: A systematic ... ...
| Abstract | Aim: Influenza infection poses a severe threat to pregnant mothers, and antiviral treatment is recommended. However, the safety of neuraminidase-inhibitor antiviral medications during pregnancy has not been well described. Methods: A systematic review and meta-analysis were performed to evaluate the adverse neonatal outcomes associated with exposure to neuraminidase inhibitors during pregnancy. The PubMed, Embase and Cochrane Library databases were searched to identify potential studies for inclusion. Results: Nine cohort studies that estimated adverse neonatal outcomes associated with exposure to neuraminidase-inhibitor medication during pregnancy were included. Exposure to a neuraminidase inhibitor during pregnancy was not associated with an increased risk of congenital malformation (odds ratio [OR] 0.9, 95% confidence interval [CI] 0.72-1.12, P = .341), low Apgar score (OR 0.96, 95% CI 0.77-1.2, P = .733) or preterm birth (OR 0.99, 95% CI 0.89-1.09, P = .771) compared with no exposure. However, exposure to a neuraminidase inhibitor was associated with a reduced risk of low birth weight (OR 0.79, 95% CI 0.68-0.92, P = .002) and giving birth to a small-for-gestational-age infant (OR 0.78, 95% CI 0.69-0.88, P < .001). Further analyses limited to oseltamivir exposure were consistent with the overall results. Conclusion: Exposure to neuraminidase-inhibitor medication during pregnancy does not appear to be associated with adverse neonatal outcomes. We recommend further studies to investigate this association, which will help clinicians determine whether to prescribe a neuraminidase inhibitor during pregnancy. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Antiviral Agents/adverse effects ; Cohort Studies ; Enzyme Inhibitors/adverse effects ; Female ; Humans ; Infant ; Infant, Newborn ; Neuraminidase ; Pregnancy ; Pregnancy Outcome/epidemiology ; Premature Birth/chemically induced | |||||
| Chemical Substances | Antiviral Agents ; Enzyme Inhibitors ; Neuraminidase (EC 3.2.1.18) | |||||
| Language | English | |||||
| Publishing date | 2021-09-02 | |||||
| Publishing country | England | |||||
| Document type | Journal Article ; Meta-Analysis ; Review ; Systematic Review | |||||
| ZDB-ID | 188974-6 | |||||
| ISSN | 1365-2125 ; 0306-5251 ; 0264-3774 | |||||
| ISSN (online) | 1365-2125 | |||||
| ISSN | 0306-5251 ; 0264-3774 | |||||
| DOI | 10.1111/bcp.15033 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 1118: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.